Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALNY 
Alnylam Pharmaceuticals Inc (ALNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: ALNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $325.06
1 Year Target Price $325.06
| 12 | Strong Buy |
| 12 | Buy |
| 7 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.49% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 41.17B USD | Price to earnings Ratio - | 1Y Target Price 325.06 |
Price to earnings Ratio - | 1Y Target Price 325.06 | ||
Volume (30-day avg) 33 | Beta 0.21 | 52 Weeks Range 205.87 - 333.70 | Updated Date 07/15/2025 |
52 Weeks Range 205.87 - 333.70 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.49% | Operating Margin (TTM) 3.04% |
Management Effectiveness
Return on Assets (TTM) -1.79% | Return on Equity (TTM) -1500.66% |
Valuation
Trailing PE - | Forward PE 2000 | Enterprise Value 39839551089 | Price to Sales(TTM) 17.53 |
Enterprise Value 39839551089 | Price to Sales(TTM) 17.53 | ||
Enterprise Value to Revenue 16.97 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 130388000 | Shares Floating 125463623 |
Shares Outstanding 130388000 | Shares Floating 125463623 | ||
Percent Insiders 3.8 | Percent Institutions 97.5 |
Upturn AI SWOT
Alnylam Pharmaceuticals Inc
Company Overview
History and Background
Alnylam Pharmaceuticals Inc. was founded in 2002 in Cambridge, MA. It pioneered RNA interference (RNAi) therapeutics, marking a significant advancement in treating genetic diseases. Key milestones include the FDA approval of Onpattro in 2018, the first RNAi therapeutic.
Core Business Areas
- RNAi Therapeutics Development: Focuses on discovering, developing, and commercializing RNAi therapeutics for genetically defined diseases.
- Commercialization: Markets and sells approved RNAi therapies globally.
- Research and Development: Continues to invest in R&D to expand its pipeline of RNAi-based drugs.
Leadership and Structure
The leadership team includes Yvonne Greenstreet, CEO. The organizational structure is based on functional departments (R&D, Commercial, Finance, etc.) and project-based teams focused on specific drug development programs.
Top Products and Market Share
Key Offerings
- Onpattro (patisiran): Indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. 2023 revenue $647M. Competitors: Pfizer's Vyndaqel/Vyndamax, Ionis Pharmaceuticals' Tegsedi.
- Givlaari (givosiran): Used to treat acute hepatic porphyria (AHP). 2023 revenue $224M. Competitors: No direct RNAi competitors, but treatments focus on managing symptoms.
- Oxlumo (lumasiran): Treats primary hyperoxaluria type 1 (PH1). 2023 revenue $155M. Competitors: No direct RNAi competitors, primarily supportive care and liver/kidney transplantation.
- Amvuttra (vutrisiran): Another RNAi therapeutic for hATTR amyloidosis with polyneuropathy, offering subcutaneous administration. Competitors: Onpattro (Alnylam) and Pfizer's Vyndaqel/Vyndamax, Ionis Pharmaceuticals' Tegsedi.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and R&D-intensive. RNAi therapeutics represent a novel class of drugs with potential for treating a wide range of diseases. Gene therapy and genetic medications market is rapidly growing.
Positioning
Alnylam is a leader in RNAi therapeutics, holding significant patents and expertise in the field. It has a first-mover advantage with several approved RNAi drugs.
Total Addressable Market (TAM)
The TAM for RNAi therapeutics is estimated to be in the billions of dollars, with continued expansion as more targets are identified and validated. Alnylam is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Pioneering RNAi technology
- FDA-approved products
- Strong patent portfolio
- Experienced management team
- Robust R&D pipeline
Weaknesses
- High R&D costs
- Reliance on single technology platform
- Market access challenges (reimbursement)
- Dependence on Key Products
Opportunities
- Expansion of RNAi technology to new diseases
- Partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies
- Global market expansion
- Positive clinical trial outcomes
Threats
- Competition from other drug modalities
- Patent challenges
- Regulatory hurdles
- Clinical trial failures
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- IONS
Competitive Landscape
Alnylam holds a leading position in RNAi therapeutics. However, competition is increasing as other companies develop alternative treatments for the same diseases. Alnylam's expertise and established platform give it a competitive edge.
Major Acquisitions
Sirna Therapeutics (partial assets)
- Year: 2014
- Acquisition Price (USD millions): 25
- Strategic Rationale: Enhanced Alnylam's intellectual property and technology related to RNAi therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Alnylam has experienced rapid revenue growth since the approval of its first product, Onpattro, in 2018.
Future Projections: Analysts project continued revenue growth driven by increased sales of existing products and the potential approval of new drugs in development. Expectations are that Amvuttra will out preform Onpattro in the future.
Recent Initiatives: Recent initiatives include expanding the indications for its existing drugs, advancing its pipeline of RNAi therapeutics, and exploring new delivery technologies.
Summary
Alnylam is a strong company at the forefront of RNAi therapeutics, with approved drugs driving significant revenue growth. Its robust pipeline and strong patent position provide a solid foundation for future growth. However, it faces challenges from competition, regulatory hurdles, and the high cost of R&D, but as the pioneer it has first movers advantages.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alnylam Pharmaceuticals Inc. Investor Relations, SEC Filings, Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2230 | Website https://www.alnylam.com |
Full time employees 2230 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.